Riskpilot← Back to searchSign inGet full accessProfound Medical Oy
OYActiveY-tunnus 2763348-1Äyritie 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 201620 employees
Revenue 2024
EUR 3,6M
+53% vs 2023
EBITDA margin
9.0%
+43% vs 2023
Equity ratio
43.1%
Financial strength
Net profit 2024
EUR 266K
+44% vs 2023
| Revenue | EUR 3,6M | +53% |
| EBITDA | EUR 326K | +43% |
| Net profit | EUR 266K | +44% |
| Total assets | EUR 3,3M | +2% |
| Equity | EUR 1,4M | +23% |
| Employees | 20 | — |
Legal name
Profound Medical Oy
Y-tunnus number
2763348-1
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
18. toukokuuta 2016
Share capital
EUR 2 500
Employees
20 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääkinnällisten laitteiden suunnittelu, kehittäminen ja valmistaminen sekä niiden myynti ja markkinointi.
Address
Äyritie 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 677 | 4 099 | 3 232 | 2 373 | 3 631 |
| Staff expenses | −943 | −1 437 | −1 527 | −1 745 | −1 650 |
| EBITDA | 225 | 174 | 325 | 228 | 326 |
| Depreciation & amort. | −94 | — | — | −0 | −0 |
| EBIT | 131 | 174 | 325 | 228 | 326 |
| Net financials | −1 | 37 | −50 | −13 | 4 |
| Profit before tax | 130 | 211 | 275 | 216 | 330 |
| Tax | 36 | 35 | 50 | 31 | 64 |
| Net profit | 94 | 176 | 224 | 184 | 266 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 024 | 1 663 | 2 223 | 3 217 | 3 279 |
| Equity | 563 | 739 | 963 | 1 148 | 1 414 |
| Long-term debt | — | — | — | 0 | 0 |
| Short-term debt | 1 460 | 924 | 1 259 | 2 070 | 1 865 |
| Total debt | 1 460 | 924 | 1 259 | 2 070 | 1 865 |
EBITDA margin
9.0%
This company
15.8%
Market median
-43% vs market
20202024
Equity ratio
43.1%
This company
38.2%
Market median
+13% vs market
20202024
Return on equity
18.8%
This company
18.4%
Market median
+2% vs market
20202024
Net profit margin
7.3%
This company
8.1%
Market median
-10% vs market
20202024
Asset turnover
1.11×
This company
1.12×
Market median
+1% vs market
20202024
Debt / equity
1.32×
This company
0.62×
Market median
-113% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MJ Person with significant control | Person with significant control | 2017 |
| Former (2) | ||
EH | Audit | 2017 – 2019 |
TM Audit | Audit | 2019 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2017 | |
| Chairperson | 2017 | |
| Board of Directors | 2017 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Profound Medical Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maureen Jean Belza | Person with significant control | 0 companies |
| Eija Hannele Niemi-Nikkola | Audit | 0 companies |
| Tuukka Miikael Kiuru | Audit | 0 companies |
| Teppo Antero Jyrkkiö | Board of Directors | 0 companies |
| Arun Swarup Menawat | Chairperson | 0 companies |
| Rashed Osman Dewan | Board of Directors | 0 companies |